Court Rules In Favor Of Mylan Over Some Teva Copaxone Patents

(RTTNews) - Mylan Inc. (MYL) said Tuesday that a judge of the U.S. District Court for the Southern District of New York has dismissed Teva Pharmaceuticals Industries Ltd.'s (TEVA) lawsuit alleging that Mylan's Abbreviated New Drug Application for its generic version of Copaxone (glatiramer acetate) would infringe four U.S. patents held by Teva.

Mylan is appealing to the Federal Circuit a separate decision involving other Teva patents, which were upheld by a retired of the Southern District of New York. Oral argument on Mylan's appeal was held on May 7. Mylan expects that a favorable appellate decision on these patents would clear Mylan for launch upon receipt of final regulatory approval.